Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer
Abstract
Purpose:
Limited literature exists regarding the safety of testosterone therapy in men treated for prostate cancer. We present multi-institutional data on testosterone therapy in hypogonadal men with prostate cancer treated with radiation therapy.
Materials and Methods:
We retrospectively reviewed the records of hypogonadal men treated with testosterone therapy after radiation therapy for prostate cancer at 4 institutions. Serum testosterone, free testosterone, estradiol, sex hormone-binding globulin, prostate specific antigen, prostate specific antigen velocity and prostate biopsy findings were analyzed.
Results:
A total of 98 men were treated with radiation therapy. Median age was 70.0 years (range 63.0 to 74.3) at initiation of testosterone therapy. Median baseline testosterone was 209 ng/dl (range 152 to 263) and median baseline prostate specific antigen was 0.08 ng/ml (range 0.00 to 0.33). In the cohort the tumor Gleason score was 5 in 3 men (3.1%), 6 in 44 (44.9%), 7 in 28 (28.6%), 8 in 7 (7.1%) and 9 in 4 (4.1%). Median followup was 40.8 months (range 1.5 to 147). Serum testosterone increased to a median of 420 ng/dl (range 231 to 711) during followup (p <0.001). Overall a nonsignificant increase in mean prostate specific antigen was observed from 0.08 ng/ml at baseline to 0.09 ng/ml (p = 0.05). Among patients at high risk prostate specific antigen increased from 0.10 to 0.36 ng/ml (p = 0.018). Six men (6.1%) met criteria for biochemical recurrence.
Conclusions:
Testosterone therapy in men following radiation therapy for prostate cancer was associated with a minor increase in serum prostate specific antigen and a low rate of biochemical recurrence.
References
- 1 : Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007; 92: 4241. Google Scholar
- 2 : Graham P and Members of British Columbia Cancer Agency Prostate Cohort Outcomes Initiative: What happens to testosterone after prostate radiation monotherapy and does it matter?. J Urol2002; 167: 2448. Link, Google Scholar
- 3 : Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol2006; 50: 935. Google Scholar
- 4 : Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol2004; 172: 920. Link, Google Scholar
- 5 : Testosterone replacement therapy after primary treatment for prostate cancer. J Urol2005; 173: 533. Link, Google Scholar
- 6 : Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol2013; 190: 639. Link, Google Scholar
- 7 : Testosterone replacement therapy following radical prostatectomy. J Sex Med2009; 6: 1165. Google Scholar
- 8 : Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res2013; 25: 24. Google Scholar
- 9 : Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int2014; 114: 125. Google Scholar
- 10 : Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int2009; 103: 62. Google Scholar
- 11 : Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer2007; 109: 536. Google Scholar
- 12 : Testosterone therapy in men with untreated prostate cancer. J Urol2011; 185: 1256. Link, Google Scholar
- 13 : Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol2005; 173: 797. Link, Google Scholar
- 14 : Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA2006; 296: 2351. Google Scholar
- 15 : Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol2003; 170: 2348. Link, Google Scholar
- 16 : Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol2010; 58: 838. Google Scholar
- 17 : Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys2003; 57: 19. Google Scholar
- 18 : Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA1999; 281: 1598. Google Scholar
- 19 : Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys1998; 41: 491. Google Scholar
- 20 : Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys1997; 38: 311. Google Scholar
- 21 : Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol2002; 168: 9. Link, Google Scholar
- 22 : Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst2008; 100: 170. Google Scholar
- 23 : Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol2012; 62: 757. Google Scholar
- 24 : The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis2014; 17: 132. Google Scholar
- 25 : Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol2009; 55: 310. Google Scholar
- 26 : Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol2011; 186: 1005. Link, Google Scholar
- 27 : Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med2014; 11: 2818. Google Scholar
- 28 : Serum PSA as a predictor of testosterone deficiency. J Sex Med2013; 10: 2518. Google Scholar
- 29 : Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl2014; 16: 864. Google Scholar
